EDTXF (Spectral Medical) Tariff Resilience Score: 5/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EDTXF Spectral Medical Inc EDTXF
10 GF Score
Price $0.95
GF Value $0.65
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Spectral Medical Tariff Resilience Score?

Spectral Medical EDTXF 10 Tariff Resilience Score is 5 as of Jul. 15, 2026. GuruFocus rates EDTXF with a GF Score™ of 10/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Spectral Medical ranks better than 75.23% on this metric.

Spectral Medical has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Spectral Medical has Medical devices may face tariffs on imported components. However, the critical nature of products may allow for some pricing power. Historical impacts have been moderate.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Spectral Medical might have Average Resilient.

Spectral Medical  (OTCPK:EDTXF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Spectral Medical Tariff Resilience Score Related Terms

EDTXF vs TMO, DHR, IDXX: Tariff Resilience Score Comparison

For the Diagnostics & Research subindustry, Spectral Medical's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spectral Medical Tariff Resilience Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Spectral Medical's Tariff Resilience Score falls into.


EDTXF
10GF Score
Spectral Medical Inc EDTXF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Spectral Medical (EDTXF) has a Tariff Resilience Score of 5 as of Jul. 15, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Spectral Medical ranks #53 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 24.8%.
Is Spectral Medical's Tariff Resilience Score too high?
Spectral Medical's current Tariff Resilience Score is 5. Based on the distribution chart, Spectral Medical ranks #53 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Spectral Medical has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's Tariff Resilience Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #53 out of 214 companies for Tariff Resilience Score. This places Spectral Medical in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Diagnostics & Research company?
A good Tariff Resilience Score depends on the Medical Diagnostics & Research industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Spectral Medical's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (EDTXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $0.95 — trading 46.2% above its estimated fair value. The current Tariff Resilience Score is 5. Spectral Medical's overall GF Score™ is 10/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Spectral Medical (EDTXF), the current Tariff Resilience Score is 5 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spectral Medical (EDTXF) Overvalued in 2026?

Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued. The current stock price of $0.95 is trading 46.2% above its estimated GF Value™ of $0.65. GuruFocus considers Spectral Medical to be Significantly Overvalued.

Key valuation signals for EDTXF:

  • Tariff Resilience Score: 5
  • GF Value™: $0.65 vs. price of $0.95 (46.2% above fair value)
  • GF Score™: 10/100 with 9 warning signs

No single metric tells the full story. See the EDTXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spectral Medical Business Description

Other Exchanges SD4:GermanyEDT:Canada
Address 135 The West Mall, Unit 2, Finance, Toronto, ON, CAN, M9C 1C2
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
10GF Score

Get the complete analysis for EDTXF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.95
Price
$0.65
GF Value